Abstract
Aims/hypothesis
MicroRNAs (miRNAs) are a novel group of small non-coding RNAs that regulate gene expression at the post-transcriptional level and act on their target mRNAs in a tissue- and cell-type-specific manner. Herein, the relevance of MIR221/MIR222 in high-glucose- and AGE-mediated vascular damage was investigated.
Methods
Functional studies were performed using human mature endothelial cells and endothelial progenitor cells subjected to high glucose or AGE. Quantitative real-time amplification was performed to analyse MIR221/MIR222 expression in these experimental conditions. Luciferase assay was used to identify MIR221/MIR222 targets. Functional studies were performed in vitro and in vivo in mice using gain- and loss-of-function approaches.
Results
Using an in vivo mouse model we demonstrated that exposure to AGE and high glucose impaired vessel formation. Moreover, in vitro functional studies revealed that both high glucose and AGE inhibit cell-cycle progression by modulating the expression of P27KIP1 (also known as CDKN1B) and P57KIP2 (also known as CDKN1C), which encode cyclin-dependent kinase inhibitor 1B (p27, Kip1) (P27KIP1) and cyclin-dependent kinase inhibitor 1C (p57, Kip2) (P57KIP2), respectively. Crucial to AGE- and high-glucose-mediated cell-cycle arrest was the downregulation of MIR221/MIR222 expression. Luciferase assay showed that MIR221 and MIR222 specifically bind to the P27KIP1 and P57KIP2 mRNA 3′-untranslated regions, implicating P27KIP1 and P57KIP2 as MIR221/MIR222 targets. These results were confirmed by gain-of-function experiments in vitro, and by injecting mice with endothelial cells overexpressing MIR221 and MIR222.
Conclusions/interpretation
We provide evidence that high-glucose- and AGE-induced inhibition of vascular cell proliferation is controlled by MIR221/MIR222-driven post-transcriptional regulation of P27KIP1 and P57KIP2. These data add further insight to the possible contribution of miRNAs in vascular damage mediated by a high-glucose environment.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Risk factors for coronary artery disease may modify an individual’s capacity for angiogenesis. Specifically, diabetes has been shown to be associated with a significant impairment in adaptive vascular growth of both capillary-like tube vessels and collateral vessels [1, 2]. Increasing evidence indicates that high glucose and AGEs are the initiating causes of vascular damage in diabetes [3, 4], acting on both resident endothelial cells (ECs) and endothelial progenitor cells (EPCs) [5, 6]. Although multiple growth factors have been shown to regulate vascular growth, little is known about the complex upstream regulation of gene expression and translation in these settings. MicroRNAs (miRNAs) are an emerging class of highly conserved non-coding small RNAs that regulate gene expression at the post-transcriptional level by inhibiting the translation of protein from mRNA or by promoting degradation of mRNA. More than 500 human miRNAs have been identified so far, and increasing evidence indicates that miRNAs have distinct expression profiles and play crucial roles in various physiological and pathological processes such as cardiogenesis, haematopoietic lineage differentiation and oncogenesis [7–10]. Meanwhile, a few specific miRNAs that regulate endothelial cell functions and angiogenesis have been described [7, 11]. miRNAs that regulate angiogenesis include MIR17-5p (also known as MIR17), MIR-17-92 (also known as MIR17HG), MIR21, MIR27A, MIR27B, MIR126, MIR130A, MIR210, MIR221, MIR222, MIR378 and the LET-7 family, MIR27B and MIR130A have been identified as pro-angiogenic miRNAs [7, 11]. In contrast, MIR221 and MIR222 inhibit endothelial cell migration and proliferation by targeting the stem cell factor receptor C-KIT [12] and, as recently shown, by targeting STAT5A [13].
MIR221 and MIR222 were originally described as potent regulators of cell-cycle progression via direct targeting of cyclin-dependent kinase inhibitor 1B (p27, Kip1) (P27KIP1) and cyclin-dependent kinase inhibitor 1C (p57, Kip2) (P57KIP2) in various human malignancies [14]. P27KIP1 and P57KIP2, together with cyclin-dependent kinase inhibitor 1A (p21, Cip1) (P21CIP1), are members of the CIP/KIP family of cyclin-dependent kinases inhibitors (CKIs) that share homology in their N-terminal regions and affect the complexes of cyclin-dependent kinases (CDKs) 2, 4 and 6 with cyclin A, D and E [15]. The CIP/KIP family proteins block the progression through all stages of the gap 1 (G1)/DNA synthesis (S) phase of the cell cycle, thereby functioning as a ‘brake of cell cycle’ [16]. Consistently, in vascular smooth muscle cells (SMCs) P27KIP1 and P57KIP2 act as cell-cycle regulatory proteins under the control of MIR221/MIR222 activity [17], indicating that MIR221 and MIR222, in addition to controlling tumour progression, might also regulate vascular cell biology.
Recently, an miRNA signature in insulin target tissues has been reported [18], and a plasma miRNA profile in type 2 diabetes revealed loss of endothelial MIR126 [19]. MIR126 plays a pivotal role in maintaining endothelial cell homeostasis and vascular integrity by facilitating vascular endothelial growth factor (VEGF) signalling [20], thus suggesting that aberrant regulation of miRNAs might actually be crucial in dictating anti-angiogenic signals in the diabetic setting.
The present study aimed to investigate the contribution of MIR221/MIR222 to high-glucose- and AGE-driven vascular damage.
Methods
Reagents and antibodies, RNA isolation and quantitative real-time PCR for miRNAs or P27KIP1 (also known as CDKN1B) and P57KIP2 (also known as CDKN1C) expression, western blot analysis and immunofluorescence analysis are described in detail in the electronic supplementary material (ESM).
Isolation and culture of ECs
ECs were isolated from human umbilical vein within 4 h of delivery by trypsin treatment (0.1% [wt/vol.]), cultured in M199 with the addition of 20% (vol./vol.) bovine calf serum (BCS) and 5 ng/ml of basic fibroblast growth factor (bFGF) and used at early passage (II–III). Throughout the study ECs were cultured for 2 days in normal medium (5 mmol/l d-glucose) plus 10% (vol./vol.) BCS and bFGF (5 ng/ml) alone or in combination with 400 μg/ml AGE, 25 mmol/l d-glucose or 19 mmol/l d-mannitol (used as osmotic control). In selected experiments, ECs exposed to normal medium, AGE or high glucose were transfected for 48 h with pre-miRNA-negative control, pre-MIR221 or pre-MIR222 precursor oligonucleotides or, alternatively, with anti-miRNA-negative control, anti-MIR221 or anti-MIR222 antagonists (Applied Biosystems, Foster City, CA, USA), according to the manufacturer’s instructions.
Isolation, characterisation and culture of EPCs from peripheral blood mononuclear cells
The following method was used to isolate EPCs. Peripheral blood mononuclear cells (PBMNCs) were obtained by Ficoll Histopaque 1077 (Sigma-Aldrich, St Louis, MO, USA) and plated onto collagen-1-coated dishes for 21 days in EGM-2 medium (Cambrex, Walkersville, MD, USA), as described by Yoder et al. [21]. FACS analysis was used to characterise EPC surface markers (anti-CD45, anti-CD14, anti-CD34, anti-CD31, anti-kinase insert domain receptor (KDR) and anti-CD146) at day 0 (2 days after isolation), when non-adherent cells were removed and at day 23, at the end of the experiments (21 days of EGM-2 culture plus 2 days with the stimuli: 400 μg/ml AGE, 25 mmol/l d-glucose glucose (‘high glucose’) or 19 mmol/l d-mannitol (‘high mannitol’)). The control conditions were 5 mmol/l d-glucose (‘normal’). Approval was obtained both from Servizio Immunoematologia e Medicina Trasfusionale and from the Institutional Review Board of S. Giovanni Battista Hospital, Turin, Italy. Informed consent was provided according to the Declaration of Helsinki. In selected experiments, EPCs exposed to normal medium, AGE or high glucose were transfected for 48 h with pre-miRNA-negative control, pre-MIR221 or pre-MIR222 precursor oligonucleotides or, alternatively, with anti-miRNA-negative control, anti-MIR221 or anti-MIR222 antagonists (Applied Biosystems), according to the manufacturer’s instructions.
Flow cytometry
To analyse cell-cycle progression, ECs and EPCs treated for 2 days as indicated were processed by FACS analysis, as previously described by Defilippi et al. [22]. Briefly, after treatment, the cells were fixed with 70% (vol./vol.) ethanol and DNA was stained with propidium iodide (Sigma-Aldrich) and analysed with a flow cytometer (FACScan, Becton Dickinson, San Jose, CA, USA). The percentage of cells in each phase of the cell cycle was determined by ModFit LT software (Verity Software House, Topsham, ME, USA). The percentage of the cells in the DNA duplicating phase (S phase) was reported. Cell-cycle analysis by FACS was also performed on: (1) ECs treated with different AGE concentration (from 50 to 1,200 μg/ml); and (2) ECs and EPCs transfected for 48 h with pre-miRNA-negative control, pre-MIR221 or pre-MIR222 precursor oligonucleotides or, alternatively, with anti-miRNA-negative control, anti-MIR221 or anti-MIR222 antagonists in normal conditions or in the presence of AGE, high glucose or high mannitol.
In vitro endothelial cell migration assay
Analysis of chemotaxis of ECs was performed as previously described by Brizzi et al. and Dejana et al. [23, 24]. Briefly, assessment of EC migration was performed in Boyden’s chambers by counting the cells that passed across the filter (8 μm pore size) after addition in the lower compartment of the chamber of the vehicle alone (free medium with 0.25% [wt/vol.] BSA), high glucose (25 mmol/l), high mannitol (19 mmol/l), or AGE (400 μg/ml), in the presence of VEGF (20 ng/ml). Cell counting was performed by three different operators on 10 fields, ×20 magnification, of three individual experiments (n = 9).
Luciferase miRNA target reporter assay
The luciferase reporter assay was performed using a construct generated by subcloning the PCR products amplified from full-length 3′-untranslated region (UTR) of P27KIP1 and 3′-UTR of P57KIP2 DNA in the SacI restriction site of the luciferase reporter vector plasmid miR (pmiR) (Ambion, Applied Biosystems). The PCR products were obtained using the following primers: P27KIP1 sense 5′-AGAGCTCCAGATACATCACTGC-3′, antisense 5′-TGAGCTCTATACTTGGCTCAG-3′; P57KIP2 sense 5′-TTGAGCTCCCCTTCTTCTCGCTGTCCTCT-3′, antisense 5′-AAGAGCTCCTCTTTGGGCTCTAAATTGGC-3′.
The insert identities were verified by sequencing. The pmiR, pmiR-3′-UTR-P27KIP1 and pmiR-3′-UTR-P57KIP2 reporter vectors were transiently co-transfected in ECs and EPCs, cultured in normal medium alone or in combination with 400 μg/ml AGE or 25 mmol/l d-glucose or 19 mmol/l d-mannitol, at 30:1 molar ratio with the pRL vector, coding for the Renilla sp. luciferase, used as the internal control of the luciferase assay. Luciferase activities were analysed 48 h later by Dual-Luciferase Report Assay System (Promega, Madison, WI, USA), according to the vendor’s instructions, using a TD20/20 double injector luminometer (Turner Designs, Forlì, Italy). The results were expressed as relative luciferase activity (%), calculated by normalising the ratio of the firefly/Renilla sp. luminescences. Luciferase activities, using the pmiR reporter vectors, described above, were also evaluated in ECs or in EPCs, transfected 24 h previously with pre-miRNA negative control, pre-MIR221 or pre-MIR222 precursor oligonucleotides.
In vivo experiments
For the murine angiogenesis assay FVB mice (five mice, 8 weeks old, for each experimental group) (Charles River Laboratories International, Wilmington, MA, USA) were injected s. c. with Matrigel containing VEGF (50 ng/ml) [25, 26], high glucose (25 mmol/l), and AGE (400 μg/ml) alone or in combination as indicated. The negative control was NaCl solution (154 mmol/l). After 7 days, the FVB mice were killed and Matrigel plugs were processed for histological analysis with haematoxylin–eosin staining. In selected experiments for the angiogenesis assay, SCID mice (five mice, 7 weeks old, for each experimental group) (Charles River Laboratories) were injected s.c. with growth-factor-reduced Matrigel containing VEGF, AGE and 2 × 106 ECs, previously transfected with pre-miRNA negative control, pre-MIR221 or pre-MIR222 precursors and processed as described by Zeoli et al. [27].
Briefly, 4 days after injection Matrigel plugs were recovered and fixed in 10% (vol./vol.) buffered formalin and embedded in paraffin for histological and immunofluorescence analyses or digested for EC isolation. The vessel area and the total Matrigel area were planimetrically assessed from haematoxylin–eosin-stained sections as previously described by Zeoli et al. [27]. Only the structures possessing a patent lumen and containing erythrocytes were considered vessels. Angiogenesis was expressed as the percentage ± SD of the vessel area relative to the total Matrigel area (% vessel area, ×10 magnification). Quantification of neo-formed vessels was also evaluated by CD31 staining of vascular ECs. Any stained EC or EC cluster, clearly separated from connective tissue elements, was considered as a single microvessel and counted according to Weidner et al. [28]. Animal procedures conformed to the Guide for Care and Use of Laboratory Resources (National Institutes of Health publication no. 93–23, revised 1985) [29].
Isolation of ECs from Matrigel plugs
ECs were recovered from Matrigel plugs 4 days after injection into SCID mice [30]. After digestion in Hank’s buffered salt solution containing 0.1% (vol./vol.) collagenase I for 30 min at 37°C, the cells were washed in medium plus 10% (vol./vol.) BCS and forced through a graded series of meshes to separate the cell component from Matrigel matrix. ECs were isolated via anti-human CD31 antibody coupled to magnetic beads, by magnetic cell sorting using the MACS system (Miltenyi Biotec, Auburn, CA, USA). Briefly, cells were labelled with the anti-human CD31 antibody for 20 min and then were washed twice and re-suspended in MACS buffer (PBS without Ca2+ and Mg2+, supplemented with 1% [vol./vol.] BSA and 5 mmol/l EDTA) at the concentration of 0.5 × 106 cells/80 μl. After washing, cells were separated on a magnetic stainless steel Wool column (Miltenyi Biotec) according to the manufacturer’s recommendation. The endothelial phenotype was verified by FACS analysis using an anti-human von Willebrand antibody (Sigma-Aldrich). The recovered cells were subjected to RNA isolation to detect MIR221 and MIR222 expression by quantitative real-time PCR or lysed for western blot analysis.
Statistical analysis
All in vitro and in vivo results are representative of at least three independent experiments, performed in triplicate. Densitometric analysis using a BioRad GS 250 molecular imager was used to calculate the differences in the fold induction of protein content, reported as ‘densitometric value’ and each western blot panel and relative densitometric histogram shown in the figures was representative of the results obtained in triplicate. The significance of differences between experimental and control values for both in vitro and in vivo experiments was calculated using analysis of variance with Newman–Keuls multi-comparison test and reported in detail in each figure legend (n = 9).
Results
High glucose and AGE impair EC and EPC proliferation and neo-vessel formation in mice
Increasing evidence indicates that the vascular damage occurring in diabetes is the result of repeated acute changes in cellular glucose metabolism, or long-term accumulation of AGE [3, 4]. Thus, the effects of high glucose and AGE on EC functional activities were investigated. First, an AGE dose–response curve was constructed. The percentage of ECs in the different cell-cycle phases was evaluated and reported in ESM Fig. 1. As we failed to detect significant differences from 50 to 1,200 μg/ml of AGE, 400 μg/ml of AGE was used throughout the study.
We further compared the effects of AGE with those of high glucose. Data reported in Fig. 1a demonstrate that, as with AGE, high-glucose treatment prevented EC progression into the cell cycle. In addition, high glucose and AGE both decreased migration of ECs in response to VEGF (Fig. 1c). High mannitol was used as osmotic control throughout the study.
Vascular remodelling does not exclusively rely on proliferation of resident ECs, but also involves EPCs [31]. Thus, EPCs were isolated and characterised according to Yoder et al. [21] (ESM Figs 2–5 and ESM Table 1) and cultured in the presence of high glucose and AGE. Again, we found that cell-cycle progression was prevented when EPCs were exposed to high glucose and AGE (Fig. 1b), suggesting that exposure to AGE or high glucose might also hinder in vivo vessel formation. To investigate the in vivo effects of AGE and high glucose, a mouse model of angiogenesis was used. Data reported in Fig. 1d,e demonstrate that vessel formation in response to a well-known angiogenic stimulus, VEGF [25, 26], was prevented in the presence of AGE and high glucose.
MIR221 and MIR-222 targeting P27KIP1 and P57KIP2 are crucial for high-glucose- and AGE-mediated inhibition of cell-cycle progression in vascular cells
New vessel formation is controlled by a complex network of genes, and two short non-coding RNAs—MIR221 and MIR222—have emerged as critical regulators of gene expression in this setting [7–11]. Thus, the biological relevance of MIR221 and MIR222 in high-glucose- and AGE-mediated inhibition of cell-cycle progression of vascular cells was investigated. To this end ECs and EPCs subjected to AGE or high glucose were first analysed for MIR221 and MIR222 expression by quantitative real-time PCR. As shown in Fig. 1f,g a significant downregulation of both miRNAs was detected. In contrast, high mannitol had no effect on their expression. P27KIP1 and P57KIP2 have been described as target genes involved in MIR221/MIR222-induced SMC proliferation [17]. Data presented in Fig. 2 demonstrate that both stimuli increased P27KIP1 and P57KIP2 protein levels without affecting their mRNA levels (Fig. 2a–d). To confirm these results a luciferase reporter vector containing the full-length P27KIP1-3′-UTR or P57KIP2-3′-UTR was transfected in ECs and EPCs. As reported in Fig. 2e,f, luciferase activity was detected in AGE- and high-glucose-cultured ECs and EPCs, but not in cells treated with high mannitol. These data indicate that, as the result of MIR221 and MIR222 downregulation, post-transcriptional regulation of P27KIP1 and P57KIP2 controls high-glucose- and AGE-induced inhibition of both EC and EPC cell-cycle progression.
Gain- and loss-of function approaches identify MIR221 and MIR222 as crucial regulators of high-glucose- and AGE-induced inhibition of cell-cycle progression
To confirm the above data, biochemical and functional studies using gain-of-function and loss-of-function approaches were performed in ECs and EPCs (ESM Fig. 6). In accordance with the role of P27KIP1 and P57KIP2 expression in controlling cell-cycle progression, AGE- and high-glucose-induced cell-cycle arrest was prevented by overexpressing pre-MIR221 and pre-MIR222 (Fig. 3a,c). Consistent with these findings, anti-MIR221 and anti-MIR222 overexpression led to a decreased number of cells in the S-phase that could not be further affected by the addition of AGE or high glucose (Fig. 3b,d). To ascertain the direct effect of MIR221 and MIR222 on P27KIP1-3′-UTR and P57KIP2-3′-UTR, the luciferase reporter vectors containing the full-length 3′-UTRs were transfected in both cell types. As expected, in P27KIP1- or P57KIP2-3′-UTR-expressing cells, pre-MIR221 and pre-MIR222 overexpression led to a decreased luciferase activity that, again, could not be enhanced by the addition of high glucose or AGE (Fig. 3e–h). As the expression of P27KIP1 or P57KIP2 correlated with that of the related miRNAs, we assumed that pre-miRNAs were able to act on their specific targets (Fig. 4). Thus, a mouse model was used to investigate the biological relevance of MIR221 and MIR222 in vivo.
High-glucose and AGE-mediated inhibition of vessel formation in vivo in mice is controlled by MIR221 and MIR222
The involvement of MIR221 and MIR222 in high-glucose- and AGE-mediated vascular damage was evaluated in an in vivo model of angiogenesis. To this end SCID mice were injected with Matrigel plugs containing VEGF [25, 26], AGE and ECs overexpressing MIR221, MIR222 or the negative control. Results reported in Fig. 5a demonstrate that, unlike in Matrigel-containing cells transfected with the negative control, in Matrigel-containing ECs overexpressing pre-MIR221 or pre-MIR222, functional vessels could be detected (erythrocytes are present in their lumen). Similar results were obtained with high glucose (data not shown). High mannitol was used as the control (ESM Fig. 7). To exclude the possibility that newly formed vessels were derived from cells of host origin, an immunofluorescence assay was performed using an anti-human CD31-antibody. In Fig. 5a, CD31-stained vessels are shown. Consistent with this, biochemical analysis of ECs from the same Matrigel plugs revealed almost undetectable levels of P27KIP1 and P57KIP2 proteins in samples overexpressing MIR221 and MIR222 (Fig. 5c,d). Taken together, these data indicate that MIR222- and MIR221-driven post-transcriptional regulation of P27KIP1 and P57KIP2 is crucial for high-glucose- and AGE-induced vascular cell damage in vivo.
Discussion
The present study demonstrates: (1) high glucose and AGE induce inhibition of vascular cell progression in the cell cycle; (2) this effect is recapitulated in vivo in a mouse model of angiogenesis; and (3) under high glucose and AGE stress MIR221- and MIR222-driven post-transcriptional regulation of P27KIP1 and P57KIP2 controls cell-cycle progression of vascular cells both in vitro and in vivo in mice.
Endothelial injury is thought to represent a crucial step in the initiation and progression of vascular diseases in the diabetic setting. Acute changes in cellular glucose metabolism or accumulation of AGE, in addition to accelerating endothelial cell damage, also abate endothelial repair mechanisms. Vascular repair processes not only rely on resident endothelial cells but also on circulating EPCs [31]. Compelling evidence indicates that changes in EPC number and functional activities are closely associated with cardiovascular risk factor profiles [31, 32], impacting on their delivery to sites of ischaemia, where angiogenesis might be required. Studies addressed to evaluate the functional role of EPCs in supporting neovascularisation have often provided controversial evidence. In particular, the use of different assays for EPC expansion and the reliance on cell-surface markers and morphology in the absence of functional assays have contributed to this confusion [33]. Currently, EPC designation is based on EPC functional features and, in particular, on their in vivo vasculogenic capability [34, 35]. In the present study, by using EPCs previously shown to have vasculogenic capability when injected in collagen matrix in mice [36, 37], we were able to demonstrate that cell-cycle progression of EPCs was blocked under high-glucose and AGE stress. A similar effect was observed when ECs were exposed to high glucose and AGE, suggesting that high glucose concentrations or accumulation of AGE might exert a damaging effect in vivo. Indeed, AGE and high glucose were both able to prevent recruitment, proliferation and formation of vascular structures when injected in SCID mice together with a potent angiogenic stimulus such as VEGF [25, 26]. Progression into the cell cycle is a pre-requisite for cell proliferation. The cell cycle is controlled by a series of regulatory molecules known as cyclins, CDKs and CKIs. P27KIP1 and P57KIP2 belong to the CIP/KIP family of CKIs [15, 16] and act as a ‘brake of cell cycle’ as they exert a stringent control on all stages of the G1/S phase [15, 16]. The increased expression of P27KIP1 and P57KIP2 in response to high glucose and AGE stress supports the results of our functional studies.
Improvement in angiogenesis after critical ischaemia is of considerable interest as a therapeutic strategy. However, little is known about the complex regulation of gene expression during neovascularisation and vascular remodelling. miRNAs are a recently recognised class of highly conserved non-coding short RNA molecules that are considered fine-scale rheostats of protein-coding gene product abundance [7, 38]. The relative importance and mode of action of miRNAs in human complex diseases remain to be fully elucidated. Recently, miRNAs have been shown to be directly involved in cardiovascular diseases [7]. Moreover, in diabetes, miRNAs have been implicated in the epigenetic regulation of key metabolic, inflammatory, and anti-angiogenic pathways [39]. At this regard, a recent plasma miRNA signature in diabetic patients demonstrates loss of the vascular regulatory miRNA, MIR126 [19]. Herein, we demonstrate that two additional angiogenic regulatory miRNAs, MIR221 and MIR222, are downregulated in response to high glucose and AGE stress. It has been proposed that MIR221 and MIR222 are oncogenic, based on their upregulation in tumour cells and on their suppressive effects on the production of the CKI protein P27KIP1 [40–42]. However, MIR221/MIR222 were subsequently recognised as being critical for the proliferation of SMC via their target gene products, P27KIP1 and P57KIP2 [17]. We herein provide evidence that high-glucose- and AGE-mediated inhibition of cell-cycle progression as well as neo-vessel formation in mice are controlled by MIR221/MIR222-driven post-transcriptional regulation of P27KIP1 and P57KIP2. These results, together with data demonstrating that loss of pro-angiogenic MIR126 in endothelial apoptotic bodies correlates with plasma glucose concentrations [19], reveal additional molecular details to explain the defective adaptive vascular growth associated with diabetes.
One important feature of miRNA is tissue- and cell-specific expression pattern. However, it is becoming even more evident that the cell microenvironment dictates miRNA target specificity. This is particularly true in vascular cell biology, in which discrete targets, such as STAT5A [13] or, as reported herein, P27KIP1 and P57KIP2, are post-transcriptionally regulated by MIR221/MIR222 when vascular cells are exposed to an inflammatory microenvironment [13] or to high glucose and AGE stress, respectively.
Clinical studies have demonstrated that the level of the circulating AGE may be linked to various diabetes complications [43]. However, until recently the sophisticated and expensive laboratory techniques required for measurement of specific AGEs have retarded any attempts at widespread use of such measurements in the clinic. Moreover, as AGEs are structurally heterogeneous, it remains unclear which circulating AGE should be measured. Similarly, AGE accumulates in tissues [3], and thus the level of AGE able to promote cell injuries remains to be established. For these reasons, to date, in vitro studies have been performed using concentrations ranging from 0.2 to 2 mg/ml [44–46]. The AGE concentration used throughout this study was chosen on the basis of a dose–response curve, which allowed us to define the boundary between harmless and damaging AGE concentrations in our experimental models. We are aware of the intrinsic limitations of in vitro studies; however, the validity of the results obtained with the selected AGE dosage is supported by the findings that inhibition of cell-cycle progression and downregulation of MIR221 and MIR222 expression also occurred when vascular cells were challenged with high glucose.
We are confident that our in vitro study presents a number of limitations mainly through the absence of a specific stromal microenvironment that, in vivo, may contribute to the response to AGE stress. In addition, ECs or EPCs used in vitro can be only considered surrogates of in vivo vascular cells located in a vessel microenvironment containing regulatory molecules that again can influence the response to AGE stress. Finally, in vivo studies in mice present, per se, a limitation as they may not reproduce the complexity of human model and can only provide speculative conclusions. Additional concerns may also derive from in vitro and in vivo mouse models in which natural molecules are artificially produced in abundance. Nonetheless, in vitro studies and mouse models are currently recognised as valuable tools as they may provide rational bases to set methods appropriate for human studies that, in this particular setting, may be able to assess the real impact of AGE in driving vascular damage.
Emerging evidence suggests that miRNAs play significant roles in insulin production, action and secretion and also in diverse aspects of glucose and lipid metabolism [18, 19]. Most importantly, microarray studies have highlighted an altered miRNA profile in insulin target tissues in diabetic models [18] and patients [19]. The results reported herein provide evidence that deregulation of MIR221 and MIR222 expression, together with loss of MIR126 [19], might dictate and sustain high-glucose-driven anti-angiogenic signals. To boot, the finding that neo-vessel formation in response to high glucose and AGE stress is under the control of miRNA expression [19] identifies miRNAs as potential targets for pharmacological intervention to ameliorate vascular dysfunction in pathological settings, such as those associated with altered glucose metabolism.
Abbreviations
- BCS:
-
Bovine calf serum
- bFGF:
-
Basic fibroblast growth factor
- CDK:
-
Cyclin-dependent kinase
- CKI:
-
Cyclin-dependent kinase inhibitor
- DAPI:
-
2-(4-Amidinophenyl)-6-indolecarbamidine
- ECs:
-
Endothelial cells
- EPCs:
-
Endothelial progenitor cells
- KDR:
-
Kinase insert domain receptor
- miRNA:
-
MicroRNA
- P27KIP1:
-
Cyclin-dependent kinase inhibitor 1B (p27, Kip1)
- P57KIP2:
-
Cyclin-dependent kinase inhibitor 1 C (p57, Kip2)
- G0/G1/G2 :
-
Gap 0/1/2 (cell cycle)
- M:
-
Mitosis (phase cell cycle)
- PBMNCs:
-
Peripheral blood mononuclear cells
- SMCs:
-
Smooth muscle cells
- S phase:
-
DNA synthesis phase (cell cycle)
- 3′-UTR:
-
3′-Untranslated region
- VEGF:
-
Vascular endothelial growth factor
References
Abaci A, Oğuzhan A, Kahraman S et al (1999) Effect of diabetes mellitus on formation of coronary collateral vessels. Circulation 99:2239–2242
Chen CH, Jiang W, Via DP et al (2000) Oxidized low-density lipoproteins inhibit endothelial cell proliferation by suppressing basic fibroblast growth factor expression. Circulation 101:171–177
Wautier JL, Schmidt AM (2004) Protein glycation: a firm link to endothelial cell dysfunction. Circ Res 95:233–238
Yan SF, Ramasamy R, Schmidt AM (2010) The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature. Circ Res 106:842–853
Callaghan MJ, Ceradini DJ, Gurtner GC (2005) Hyperglycemia-induced reactive oxygen species and impaired endothelial progenitor cell function. Antioxid Redox Signal 7:1476–1482
Chen YH, Lin SJ, Lin FY et al (2007) High glucose impairs early and late endothelial progenitor cells by modifying nitric oxide-related but not oxidative stress-mediated mechanisms. Diabetes 56:1559–1568
Urbich C, Kuehbacher A, Dimmeler S (2008) Role of microRNAs in vascular diseases, inflammation, and angiogenesis. Cardiovasc Res 79:581–588
Havelange V, Garzon R (2010) MicroRNAs: emerging key regulators of hematopoiesis. Am J Hematol 85:935–942
Fish JE, Srivastava D (2009) MicroRNAs: opening a new vein in angiogenesis research. Sci Signal 2:pe1
Fazi F, Nervi C (2008) MicroRNA: basic mechanisms and transcriptional regulatory networks for cell fate determination. Cardiovasc Res 79:553–561
Suárez Y, Sessa WC (2009) MicroRNAs as novel regulators of angiogenesis. Circ Res 104:442–454
Poliseno L, Tuccoli A, Mariani L et al (2006) MicroRNAs modulate the angiogenic properties of HUVECs. Blood 108:3068–3071
Dentelli P, Rosso A, Orso F et al (2010) MicroRNA-222 controls neovascularization by regulating signal transducer and activator of transcription 5A expression. Arterioscler Thromb Vasc Biol 30:1562–1568
Calin GA, Croce CM (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6:857–866
Besson A, Dowdy S, Roberts JM (2008) CDK inhibitors: cell cycle regulators and beyond. Dev Cell 14:159–169
Sherr CJ, Roberts JM (1999) CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13:1501–1512
Liu X, Cheng Y, Zhang S, Lin Y, Yang J, Zhang C (2009) A necessary role of miR-221 and miR-222 in vascular smooth muscle cell proliferation and neointimal hyperplasia. Circ Res 104:476–487
Herrera BM, Lockstone HE, Taylor JM et al (2010) Global microRNA expression profiles in insulin target tissues in a spontaneous rat model of type 2 diabetes. Diabetologia 53:1099–1109
Zampetaki A, Kiechl S, Drozdov I et al (2010) Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res 107:810–817
Nicoli S, Standley C, Walker P, Hurlstone A, Fogarty KE, Lawson ND (2010) MicroRNA-mediated integration of haemodynamics and Vegf signalling during angiogenesis. Nature 464:1196–1200
Yoder MC, Mead LE, Prater D et al (2007) Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood 109:1801–1809
Defilippi P, Rosso A, Dentelli P et al (2005) β1 Integrin and IL-3R coordinately regulate STAT5 activation and anchorage-dependent proliferation. J Cell Biol 168:1099–1108
Brizzi MF, Battaglia E, Montrucchio G et al (1999) Thrombopoietin stimulates endothelial cell motility and neoangiogenesis by a platelet-activating factor-dependent mechanism. Circ Res 84:785–796
Dejana E, Languino LR, Polentarutti N et al (1985) Interaction between fibrinogen and cultured endothelial cells. Induction of migration and specific binding. J Clin Invest 75:11–18
Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669–676
Ferrara N (2009) Vascular endothelial growth factor. Arterioscler Thromb Vasc Biol 29:789–791
Zeoli A, Dentelli P, Rosso A et al (2008) Interleukin-3 promotes expansion of hemopoietic-derived CD45+ angiogenic cells and their arterial commitment via STAT5 activation. Blood 112:350–361
Weidner N, Semple JP, Welch WR, Folkman J (1991) Tumor angiogenesis and metastasis—correlation in invasive breast carcinoma. N Engl J Med 324:1–8
National Research Council (1996) Guide of care and use of laboratory animals. National Academy Press, Washington, NIH publication no. 93–23
Dentelli P, Rosso A, Balsamo A et al (2007) C-KIT, by interacting with the membrane-bound ligand, recruits endothelial progenitor cells to inflamed endothelium. Blood 109:4264–4271
Hristov M, Weber C (2008) Endothelial progenitor cells in vascular repair and remodeling. Pharmacol Res 58:148–151
Hill JM, Zalos G, Halcox JP et al (2003) Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 348:593–600
Yoder MC, Ingram DA (2009) The definition of EPCs and other bone marrow cells contributing to neoangiogenesis and tumor growth: is there common ground for understanding the roles of numerous marrow-derived cells in the neoangiogenic process? Biochim Biophys Acta 1796:50–54
Schatteman GC, Dunnwald M, Jiao C (2007) Biology of bone marrow-derived endothelial cell precursors. Am J Physiol Heart Circ Physiol 292:H1–H8
Critser PJ, Yoder MC (2010) Endothelial colony-forming cell role in neoangiogenesis and tissue repair. Curr Opin Organ Transplant 15:68–72
Togliatto G, Trombetta A, Dentelli P et al (2010) Unacylated ghrelin rescues endothelial progenitor cell function in individuals with type 2 diabetes. Diabetes 59:1016–1025
Uberti B, Dentelli P, Rosso A, Defilippi P, Brizzi MF (2010) Inhibition of β1 integrin and IL-3Rβ common subunit interaction hinders tumour angiogenesis. Oncogene 29:6581–6590
Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281–297
Pandey AK, Agarwal P, Kaur K, Datta M (2009) MicroRNAs in diabetes: tiny players in big disease. Cell Physiol Biochem 23:221–232
Gillies JK, Lorimer IA (2007) Regulation of p27Kip1 by miRNA 221/222 in glioblastoma. Cell Cycle 6:2005–2009
le Sage C, Nagel R, Agami R (2007) Diverse ways to control p27Kip1 function: miRNAs come into play. Cell Cycle 6:2742–2749
le Sage C, Nagel R, Egan DA et al (2007) Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J 26:3699–3708
Goh SY, Cooper ME (2008) Clinical review: the role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab 93:1143–1152
Nakamura N, Obayashi H, Fujii M et al (2000) Induction of aldose reductase in cultured human microvascular endothelial cells by advanced glycation end products. Free Radic Biol Med 29:17–25
Rodiño-Janeiro BK, González-Peteiro M, Ucieda-Somoza R, González-Juanatey JR, Alvarez E (2010) Glycated albumin, a precursor of advanced glycation end-products, up-regulates NADPH oxidase and enhances oxidative stress in human endothelial cells: molecular correlate of diabetic vasculopathy. Diab Metab Res Rev 26:550–558
Rubenstein DA, Morton BE, Yin W (2010) The combined effects of sidestream smoke extracts and glycated serum albumin on endothelial cells and platelets. Cardiovasc Diabetol 9:28
Acknowledgements
This work was supported by grants of the Italian Association for Cancer Research, Ricerca Finalizzata Regione Piemonte and Ministero dell’Università e Ricerca Scientifica to M. F. Brizzi. The authors have no conflicting financial interests.
Duality of interest
The authors declare no duality of interest associated with this manuscript.
Author information
Authors and Affiliations
Corresponding author
Additional information
An erratum to this article can be found online at http://dx.doi.org/10.1007/s00125-018-4569-3.
The authors are retracting this article [1]. Following publication, concerns were raised with respect to some of the western blots and the authors were asked to supply the original unmodified blots. These blots underwent image forensics analysis and the Scientific Integrity Panel of the European Association for the Study of Diabetes (EASD) concluded that:
1. the source file provided by the authors does not correspond with that used in Fig. 5d [1]
2. there is duplication between bands for β-actin (lanes 2 and 3) in Fig. 5d of [1] and bands for Akt (lanes 3 and 4) in Fig. 5D of Togliatto et al [2]
3. there is duplication of bands for p27kip1 between lanes 2 and 5 in Fig. 2b of [1]
All authors agree with this retraction.
1. Togliatto G, Trombetta A, Dentelli P, Rosso A, Brizzi MF (2011). MIR221/MIR222-driven post-transcriptional regulation of P27KIP1 and P57KIP2 is crucial for high-glucose- and AGE-mediated vascular cell damage. Diabetologia 54:1930–1940
2. Togliatto G, Trombetta A, Dentelli P et al (2010). Unacylated ghrelin rescues endothelial progenitor cell function in individuals with type 2 diabetes. Diabetes 59:1016–1025
Electronic supplementary material
Below is the link to the electronic supplementary material.
ESM Table 1
Proportions of cells expressing the surface antigens at days 0 and 23 (PDF 10 kb)
ESM Table 2
Proportions of ECs and EPCs in each cell-cycle phase (PDF 9 kb)
ESM Fig. 1
The percentage of ECs in each cell-cycle phase was evaluated 48 h after treatment with AGE at the indicated concentrations. The numbers are the mean ± SD of three different experiments performed in triplicate (n = 9). *p < 0.05 for AGE 400, 800 and 1,200 μg/ml vs. normal conditions and AGE 50, 150 and 300 μg/ml in the G0/G1 phase; † p < 0.05 for AGE 400, 800 and 1,200 vs. normal conditions and AGE 50, 150 and 300 μg/ml in the S phase; ‡ p < 0.05 for AGE 400, 800 and 1,200 μg/ml vs. normal conditions and AGE 50, 150 and 300 μg/ml in the G2/M phase. NG, normal glucose (PDF 177 kb)
ESM Fig. 2
FACS gating strategies for identification and enumeration of ‘putative’ EPCs at day 0 (collagen I adherent PBMNCs) 48 h after seeding, according to Yoder et al. [21]. The analysis was performed as follows: cells were gated based on their physical characteristics (forward scatter [FSC] vs. side scatter [SSC]) into two distinct regions (green and red). Markers defining the aspecific staining were set in agreement with the isotype controls (IgG-FITC and IgG-PE) (middle panels). Marker defining CD34+ cells was set in agreement with the physical parameter (bottom panels). FSC, forward scatter; SSC, side scatter (PDF 257 kb)
ESM Fig. 3
FACS characterisation of EPC surface markers at day 0. The gated populations (see ESM Fig. 2) are referred to as R1 in green and R2 in red. The marker defining CD34+ cells was set in agreement with the physical parameter (upper panels). FITC-conjugated anti-CD45, anti-CD14, anti-KDR, anti-CD31 and anti-CD146 and PE-conjugated anti-CD34 antibodies were used. Dot plot analysis of CD45-FITC, CD14-FITC, KDR-FITC, CD31-FITC and CD146-FITC vs. the progenitor marker CD34-PE is reported. Percentages of cells positive for the indicated markers are reported in ESM Table 1. Cells expressing CD34, CD31 and KDR included in the R2 gate were considered to be the starting EPC population (PDF 524 kb)
ESM Fig. 4
FACS gating strategies for the identification and enumeration of EPCs at day 23. The analysis was performed as follows: cells treated with the indicated stimuli were gated based on their physical characteristics (FSC vs. SSC). The analysis revealed a homogeneous population that we gated in R1. Markers defining the aspecific staining were set in agreement with the isotype controls (IgG-FITC and IgG-PE) (middle panels). Marker defining CD34+ cells was set in agreement with the physical parameter (bottom panels). HG, high glucose; NG, normal glucose (PDF 261 kb)
ESM Fig. 5
FACS characterisation of EPC surface markers at day 23. FITC-conjugated anti-CD45, anti-CD14, anti-KDR, anti-CD31 and anti-CD146 and PE-conjugated anti-CD34 antibodies were used. Dot plot analysis of CD45-FITC, CD14-FITC, KDR-FITC, CD31-FITC and CD146-FITC vs. the progenitor marker CD34-PE is reported. Percentages of cells positive for the indicated markers are reported in ESM Table 1. EPC marker expression does not change in response to the indicated stimuli. HG, high glucose; NG, normal glucose (PDF 552 kb)
ESM Fig. 6
ECs and EPCs transfected with pre-miR negative control, pre-MIR221 or pre-MIR222 precursors (left panels) or with anti-miRNA negative control, anti-MIR221 or anti-MIR222 antagonists (right panels), and treated with normal glucose, high glucose or AGE were evaluated for MIR221 and MIR222 expression by quantitative real-time-PCR. The reported data were normalised to RNU6B. Fold expression of miRNAs was representative of three independent experiments performed in triplicate (n = 9). * p < 0.05 for ECs and EPCs transfected with pre-MIR221 and pre-MIR222 or anti-MIR221 and anti-MIR222, cultured in normal glucose, high glucose or AGE vs. cells expressing the pre-miRNA-negative or anti-miRNA-negative construct cultured in normal glucose; † p < 0.05 for ECs and EPCs transfected with pre-miRNA-negative or anti-miRNA-negative constructs treated with high glucose or AGE vs. cells transfected with pre-miRNA-negative or anti-miRNA-negative constructs cultured in normal glucose (PDF 192 kb)
ESM Fig. 7
Matrigel plugs containing VEGF, high mannitol (19 mmol/l) and ECs transfected with pre-miRNA-negative control, pre-MIR221 or pre-MIR222 oligonucleotides were recovered 4 days after implantation in SCID mice. Histological analysis (×10 magnification) is reported. Quantification of neo-formed vessels was evaluated as reported in Methods and expressed as percentage ± SD of the vessel area relative to the total Matrigel area (% vessel area). Arrows indicate neo-formed vessels (PDF 285 kb)
ESM 1
(PDF 56 kb)
About this article
Cite this article
Togliatto, G., Trombetta, A., Dentelli, P. et al. RETRACTED ARTICLE: MIR221/MIR222-driven post-transcriptional regulation of P27KIP1 and P57KIP2 is crucial for high-glucose- and AGE-mediated vascular cell damage. Diabetologia 54, 1930–1940 (2011). https://doi.org/10.1007/s00125-011-2125-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00125-011-2125-5